Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
14,296 people get ABT articles and Market Currents by email alert.
Get email alerts on ABT »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
-
At These Levels, Covidien Has Room To RunStephen Barnes • Tue, Apr 30 -
-
-
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
Abbott Hopes Mitral Repair Will Be The New TAVIEP Vantage • Wed, Feb 27 -
-
-
-
-
-
-
-
Abbott Earnings Preview: What We Are WatchingTrefis • Tue, Jan 22
-
-
-
-
-
-
-
-
-
-
-
-
At These Levels, Covidien Has Room To RunStephen Barnes • Tue, Apr 30
-
-
-
-
-
-
-
-
-
-
Abbott Laboratories' Management Presents HCV Program Update (Transcript)Mon, Nov 12, 2012
-
Abbott Laboratories Q1 2010 Earnings Call TranscriptWed, Apr 21, 2010
-
Abbott Laboratories Q4 2009 Earnings Call TranscriptWed, Jan 27, 2010
-
Abbott Laboratories, Q3 2009 Earnings Call TranscriptWed, Oct 14, 2009
-
Abbott Laboratories, Q2 2009 Earnings Call TranscriptWed, Jul 15, 2009 • 1 Comment
-
Abbott Laboratories Q1 2009 Earnings Call TranscriptFri, Apr 17, 2009
-
Abbott Laboratories Q4 2008 Earnings Call TranscriptWed, Jan 21, 2009
-
at CNBC.com (Fri, 6:29PM)
-
at CNBC.com (Fri, 6:02PM)
-
at CNBC.com (May 13, 2013)
-
at MarketWatch.com (Apr 30, 2013)
-
at CNBC.com (Apr 29, 2013)
-
at CNBC.com (Apr 22, 2013)
-
at MarketWatch.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 17, 2013)
-
at CNBC.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 16, 2013)
-
at CNBC.com (Apr 14, 2013)
-
at CNBC.com (Apr 3, 2013)
-
at CNBC.com (Apr 2, 2013)
-
at MarketWatch.com (Mar 22, 2013)
-
at CNBC.com (Mar 20, 2013)
-
at CNBC.com (Mar 11, 2013)
-
at CNBC.com (Feb 14, 2013)
-
at MarketWatch.com (Jan 30, 2013)
-
at MarketWatch.com (Jan 23, 2013)
ABT vs. ETF Alternatives
Company Description
Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott's* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of health care products.
Abbott has four reportable revenue segments: Pharmaceutical Products, Diagnostic... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, January 2, 8:55 AM Abbott Labs (ABT) completes the separation of AbbVie (ABBV), its R&D-based pharmaceuticals business that will start trading on the NYSE today. Wells Fargo maintains an "Outperform" rating on Abbott's shares, citing the company's above-average growth outlook and opportunities to significantly increase its margin. Wells Fargo sets Abbott a price target of $33-$34; its shares are $32.25 premarket.(PR) Comment! [Healthcare, Top Stories]
- Monday, December 31, 2012, 4:50 PM AbbVie (ABBV) is set to replace Dell (DELL) in the S&P 100, and Federated Investors (FII) in the S&P 500 today. Additionally, Federated will replace ITT Educational Services (ESI) in the S&P MidCap 400, and ITT Educational Services will replace NCI Inc. (NCIT) in the S&P SmallCap 600. Abbott Laboratories (ABT) is spinning off AbbVie (ABBV) in a transaction expected to be completed today. (PR) 3 Comments [Healthcare, Financials, Tech, Consumer]
- Monday, December 31, 2012, 9:00 AM Not all diagnostics companies are worried at the prospect of the Supreme Court striking down patents on two cancer-related genes "owned" by Myriad (MYGN) in a decision that is due to come in 2013. Quest (DGX) says it could be a "positive development," as it would "open new opportunities to develop new testing services." Myriad, which has spent 17 years and $500M on isolating the "DNA molecules and processes," isn't so sanguine. Comment! [Healthcare]
- Friday, December 21, 2012, 6:57 AM DELL is off 1.9% premarket after being removed from the S&P 100 last evening. With a market cap below $18.5B, "it is no longer representative of the mega-cap market space." The company will be replaced in the index by Abbot Labs (ABT). Comment! [Tech, Healthcare]
- Friday, December 14, 2012, 1:59 PM Abbott Laboratories (ABT) declares quarterly dividend of $0.14/share post-split. The AbbVie board intends to declare dividend of $0.40/share totaling dividend to $0.54/share, 6% increase from prior dividend of $0.51, representing an annual yield of 3.31%. The quarterly dividend of $0.14/share will be payable on Feb. 15, to shareholders on record of Jan. 15. (PR) 5 Comments [Dividends]
- Thursday, December 13, 2012, 9:47 AM A blood test that Abbott Labs (ABT -0.4%) is developing could cut the time it takes to diagnose a heart attack by several hours, a small study of 19 healthy people indicates. The test assesses the blood for troponin, which is a protein in the heart muscle and which can indicate injury to the organ. (PR) Comment! [Healthcare]
- Thursday, December 13, 2012, 4:21 AM AstraZeneca's (AZN -1.6% in London) fostamatinib pill was inferior to Abbott Labs' (ABT) Humira in controlling rheumatoid arthritis symptoms in a Phase II trial. AstraZeneca can still pin its hopes, though, on a Phase III study in which fostamatinib is being given with other drugs. Results are due out in H1 next year. (PR) 1 Comment [Healthcare]
- Tuesday, December 11, 2012, 6:48 PM Goldman Sachs (GS) gets the nod by Warburg Pincus to explore a sale of Bausch & Lomb, the company's eye-care division. Warburg is said to be seeking at least $10B for the business. According to reports, Goldman has already contacted Sanofi (SNY), GlaxoSmithKline (GSK), and Merck (MRK) this month, and that Abbott Laboratories (ABT) will be among the other companies contacted. Comment! [Healthcare, M&A]
- Tuesday, December 11, 2012, 4:06 AM Abbott Laboratories' (ABT) AbbVie spin-off is worth more than Abbott ahead of the official split of the company in January. "When issued" trading in the two entities began yesterday in the secondary market, with the new Abbott valued at $47.9B and AbbVie $55.3B. The market cap of the combined Abbott is $103.27B. 5 Comments [Healthcare]
- Sunday, December 9, 2012, 2:27 AM The Supreme Court will review a "pay for delay" case in which Solvay, now owned by Abbott Labs (ABT), paid three generic drug companies to up to $40M a year, including Watson (WPI), to postpone making copycat versions of Solvay's Androgel testosterone treatment. The case has industry wide ramifications, with the FTC saying the practice costs customers $3.5B a year. (previous) 1 Comment [Healthcare, Top Stories]
- Friday, December 7, 2012, 8:15 PM Abbott (ABT) says the SEC has declared effective the Form 10 Registration Statement filed by AbbVie, its research-based pharmaceuticals business, clearing the way to spin the company out. Abbott expects to complete the separation of AbbVie on January 1, 2013, whereupon the special dividend, declared on November 28, will be distributed. 7 Comments [Healthcare]
- Friday, December 7, 2012, 4:41 AM The Supreme Court could say today whether it will review a case involving a "pay for delay" agreement in which a pharmaceutical company pays generic rivals tens of millions of dollars to hold off from launching copycat versions of medicines. The FTC says the practice costs customers $3.5B a year, while drug firms argue that it protects innovation. Companies that could be affected include Abbott (ABT), Watson (WPI), Merck (MRK), Bristol-Myers Squibb (BMY) and Teva (TEVA). Comment! [Healthcare, Top Stories]
- Monday, November 26, 2012, 12:57 PM Sucampo Pharmaceuticals (SCMP -0.8%) and Abbott (ABT -0.6%) launch Amitiza, a prescription medicine for the treatment of chronic constipation, in Japan. The drug was approved by the Japanese Ministry of Health, Labor and Welfare in Japan in June. ABT will promote and distribute Amitiza in Japan under the terms of a 2009 license agreement with SCMP. Comment! [Healthcare, Global & FX]
- Tuesday, November 20, 2012, 10:33 AM Generic drug maker Lupin Pharmaceuticals launches its Fenofibrate Tablets in the U.S. after receiving final approval from the FDA. Fenofibrate is the generic equivalent of Abbott's (ABT -0.1%) Tricor tablets, and are for the treatment of Hypercholesterolemia, Mixed Dyslipidemia and Severe Hypertriglyceridemia. Tricor currently represents about a $1.26B market for ABT. Comment! [Healthcare]
- Sunday, November 11, 2012, 3:19 AM Oral drugs for treating hepatitis C from Merck (MRK) and Abbott Labs (ABT) were highly effective in Phase II trials. A regimen that included Merck's MK-5172 suppressed the virus in most patients and appears to be better than the company's Victrelis. Merck now intends to conduct new studies, while Abbott has already started Phase III trials of a regimen of three of its treatments - ABT-450, boosting agent ritonavir (ABT-267) and ABT-333. Comment! [Healthcare]
- Monday, November 5, 2012, 2:34 PM AbbVie - Abbott Labs (ABT -0.1%) proprietary pharmaceuticals business once the company splits in two - is selling $14.7B in one of the biggest-ever dollar-denominated debt issues in the US high-grade market. The company is offering three-year fixed-rate, three-year floating-rate, five-year, six-year, 10-year and 30-year notes in a six-part deal that is expected to price later today. Comment! [Healthcare]
-
- View all 0 replies
-
WhisperNumber
$ABT earnings $1.51, 10 cents short of whisper number. Expected price reaction from today's open: http://seekingalpha.com/a/o4if - View all 0 replies
-
- View all 0 replies
-
Dividend Sheet
$ARR $FSC and $CNSL are the best yielding stocks goring ex-dividend tomorrow + http://stks.co/cHpB + My favorites are $CHK $ABT and $FCX - View all 0 replies
-
- View all 7 replies
-
Minutemen: Yes. See the following article (in which the author proposes selling ABBV and buying more ABT): http://on-msn.com/ZBOUmr
-
-
MagicDiligence
Stocks moving in and out of Magic Formula Investing this week - $ABT $HPQ $VCI and others http://bit.ly/ZsAULV - View all 0 replies
-
MagicDiligence
Looks like $ABT appearance in MFI is due to company split effective 1/2. I doubt it qualifies as a "legitimate" MFI stock. - View all 0 replies
-
MagicDiligence
First time I've ever seen Abbot Labs $ABT in MFI. One of the premier diversified pharma firms in the world. Definitely worth a look. - View all 0 replies
-
- View all 13 replies
-
-
Derek A. Barrett: Not sure if anyone is still following this thread, but $ABBV has hit my 50% Graham profit target so I will be selling. Great job $ABBV!
-
iadops40
ABT announces pricing of AbbVie's $14.7B private placement notes offering http://bit.ly/RCcnio - View all 0 replies
LATEST REPLIES
-
Vince Martin
My favorite funny piece ever -- rejected by SA: http://bit.ly/yAyzpH $GOOG $DENN $RGR $FOH $ABT - View all 5 replies
-
-
-
- View all 3 replies
-
-
praveenbolla: Short SPY will fetch you losses i guess, since market is going to touch new Highs Today....Big Rally ahead.
-
- View all 1 replies
-
-
- View all 4 replies
-
-
-
- View all 2 replies
-
-
-
- View all 1 replies
-
-
- View all 1 replies
-
-
- View all 1 replies
-
-
- View all 4 replies
-
-
-
- View all 1 replies
-
Chines33: Eying several options but not taking any chance in middle of range
-
- View all 6 replies
-
-
-
- View all 3 replies
-
-
-
- View all 4 replies
-
-
-
- View all 3 replies
-
Chines33: Also enjoying a fun 2,000 share postion in ESPH 1980 Rec at .47...was long 4000 cut that in half last week though on big move
-
-
- View all 3 replies
-
vinyal: correction is coming. don't go long regionals. they have had their run. -